US Patent

US10864159 — Method and composition for treating ocular hypertension and glaucoma

Method of Use · Assigned to Asahi Glass Co Ltd · Expires 2029-05-28 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method and composition for treating ocular hypertension and glaucoma using an ophthalmic aqueous composition containing PGF2α analogues.

USPTO Abstract

The present invention relates to an ophthalmic aqueous composition containing PGF2Î± analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2Î± analogues in an aqueous composition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-778`	—

Patent Metadata

Patent number: US10864159
Jurisdiction: US
Classification: Method of Use
Expires: 2029-05-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Asahi Glass Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.